Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

Breast Cancer Research and Treatment

Volumn 24, Issue 3, 1993, Pages 195-208

  Jänicke, Fritz ^a   Schmitt, Manfred ^a   Pache, Lothar ^a   Ulm, Kurt ^a   Harbeck, Nadia ^a   Höfler, Heinz ^a   Graeff, Henner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

axillary node negative patients; breast cancer; cathepsin D; inhibitor; PAI 1; prognosis; protease; uPA; urokinase

Indexed keywords

ANTIGEN; CATHEPSIN D; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; UROKINASE;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; TISSUE LEVEL; TREATMENT PLANNING;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CATHEPSIN D; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMAN; LYMPHATIC METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0027082979     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/BF01833260     Document Type: Article

References (45)

1. Plasminogen activators, tissue degradation and cancer
2. The relevance of plasminogen activators to neoplastic growth
3. Surface receptors for urokinase plasminogen activator
4. Better reception for urokinase
5. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation
6. Autocrine saturation of pro-urokinase receptors on human A431 cells
7. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase
8. Thrombosis and haemostasis
9. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA)
10. The plasmin system in human colonic tumors: an immunofluorescence study
11. Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis
12. Extracellular matrix and its enzymatic degradation in tumor invasion (A review)
13. Tumors: Wounds that do not heal
14. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma
15. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma
16. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
17. Urokinase plasminogen activator and prognosis in breast cancer
18. Urokinase-type plasminogen activator antigen and early relapse in breast cancer
19. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer
20. Clinical relevance of the urokinase-type and the tissue-type plasminogen activators and of their inhibitor PAI-1 in breast cancer
21. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas
22. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
23. How to use prognostic factors in axillary node-negative breast cancer patients
24. Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase
25. Tumor-associated fibrinolysis in human breast cancer: Detection and quantitation of the urokinase-type plasminogen activator (uPA) by ELISA and immunohistochemistry
26. Evaluation of estrogen receptor assays in human breast cancer tissue
27. Flow cytometry using paraffin-embedded tissue: Five years on
28. Regression models and life-tables
29. Testing a sequence of observations for a shift in location
30. A comparison of estimated proportional hazards models and regression trees
31. Bootstrap investigation of the stability of a Cox regression model
32. Nonparametric estimation from incomplete observations
33. Asymptotically efficient rank invariant procedures
34. Prognostic value of estrogen receptors in primary breast cancer
35. Prognostic factors for recurrence and survival in human breast cancer
36. Plasminogen activator content of gynecological tumors and their metastases
37. Secretion of plasminogen activators by human colorectal and gastric tumor explants
38. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors
39. An independent prognostic factor for metastasis of breast cancer
40. Cathepsin D and prognosis in breast cancer
41. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer
42. Indicators of prognosis in node-negative breast cancer
43. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry
44. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene